The price of false prophecy

'Many cancer trials in recent decades have measured the end joint (the outcome) in terms of additional months or years of life. Trialists have been very reluctant to measure the quality of the additional time.'

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • 10 expert briefings every fortnight (Premium only)
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)

Already a subscriber? Sign into your account here